Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK is poised to take further advantage of an array of opportunities in this sector.

A complex medicine applies novel technologies that deliver or target drugs, by modification of a pharmaceutical ingredient, formulation or using a new delivery route. Complex medicines offer the potential to combat elusive ‘undruggable’ targets and the development of medicines for conditions that are currently untreatable. They also promise higher efficacy and fewer side effects for currently treated conditions.

Drugs harnessing the potential of modified RNA, antisense and siRNA oligonucleotides, antibody–drug conjugates and nanomedicines will become as important as today’s ‘small molecule’ drugs, reaching potential market values into the hundreds of billions – if the potential can be realised through innovation support and industry collaboration.

MDC and CPI engaged with UK industry stakeholders to describe the complex medicines landscape, with insights on its current and future challenges and opportunities. 75% of those surveyed identified the need for more government help in the form of coordination and investment. Two-thirds wanted to see more collaborative partnerships in the development of complex medicines. Over 50% identified a better understanding of complex medicines by regulators as key to developing this field.

Recent successes in FDA approvals of antibody–drug conjugates (ADCs), RNA therapeutics and the UK’s regulatory leadership in coronavirus vaccines show that complex medicines are having a global impact. Lipid nanoparticles as carriers of next-generation vaccines also came to global prominence in 2021 as the platform for both the Pfizer-BioNTech and the Moderna Covid-19 vaccines.

Peter Simpson, Chief Scientific Officer of MDC, said: “This report offers us a deeper understanding of the opportunities and challenges UK innovators in complex medicines are facing. This knowledge allows us to better target the interventions provided by MDC, CPI and other key stakeholders, to ensure the UK sector is supported in their mission to get better-targeted therapies to patients faster.”

Dr Caroline Kelly, Head of Technology Strategy (Formulation) at CPI, said: “Complex medicines have the potential to treat conditions that as of today are untreatable with existing medicines. They can also offer more targeted therapies with higher efficacy and fewer side effects – a clear benefit for someone going through chemotherapy treatment for example. The market value for complex medicines is set to reach hundreds of billions of pounds, and you can see why with the potential benefits for patients.”

The report is available to download here.

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free